Clinical trial / 2015
High-dose omega-3 supplementation did not improve core autism symptoms and was linked to worsening externalizing problem scores in young children with ASD.
A 6-month randomized, placebo-controlled trial evaluated 1.5 g of omega-3 fatty acid supplements versus placebo in 38 children aged 2 to 5 years with autism spectrum disorder (ASD). There was no significant difference between groups in the 0- to 24-week change in PDDBI autism composite scores (p = 0.5), adaptive function (p = 0.09), or language gains (p = 0.6). A significant group by week interaction was observed for the BASC-2 externalizing problem score, with participants in the omega-3 group showing worsening scores (p = 0.02). Omega-3s were relatively well tolerated, and changes in cytokine profiles did not significantly correlate with treatment response.
- Study type
- Randomized, placebo-controlled trial
- Who was studied
- 38 children aged 2 to 5 years with autism spectrum disorder
- What was measured
- PDDBI autism composite score, BASC-2 externalizing problems score, CGI-I, VABS-II, PLS-4, and safety
THE PAPER
A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism.
Mankad D, Dupuis A, Smile S, Roberts W, Brian J, Lui T, Genore L, Zaghloul D, Iaboni A, Marcon PM, Anagnostou E. Mol Autism, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.